Mohit Bansal
Stock Analyst at Wells Fargo
(4.79)
# 115
Out of 4,412 analysts
106
Total ratings
70.15%
Success rate
18.64%
Average return
Main Sectors:
25 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $100 → $110 | $80.91 | +35.95% | 2 | Apr 25, 2024 | |
| NBIX Neurocrine Biosciences | Upgrades: Overweight | $140 → $170 | $135.99 | +25.01% | 7 | Apr 24, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $51 → $52 | $44.85 | +15.94% | 7 | Apr 18, 2024 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $130 → $135 | $131.20 | +2.90% | 8 | Mar 27, 2024 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $84 → $78 | $65.42 | +19.23% | 7 | Mar 4, 2024 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Overweight | $20 → $14 | $7.82 | +79.03% | 2 | Mar 1, 2024 | |
| TVTX Travere Therapeutics | Maintains: Equal-Weight | $8 → $9 | $5.26 | +71.10% | 3 | Feb 16, 2024 | |
| BIIB Biogen | Downgrades: Equal-Weight | $315 → $240 | $208.90 | +14.89% | 8 | Feb 14, 2024 | |
| LLY Eli Lilly | Maintains: Overweight | $700 → $825 | $733.51 | +12.47% | 14 | Feb 7, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $500 → $540 | $397.48 | +35.86% | 7 | Feb 6, 2024 | |
| PFE Pfizer | Maintains: Equal-Weight | $39 → $35 | $25.40 | +37.80% | 8 | Oct 17, 2023 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $875 → $980 | $883.20 | +10.96% | 9 | Aug 21, 2023 | |
| CERE Cerevel Therapeutics Holdings | Upgrades: Overweight | $30 | $42.47 | -29.36% | 3 | May 4, 2023 | |
| ABBV AbbVie | Maintains: Overweight | $200 → $195 | $159.62 | +22.17% | 3 | Apr 28, 2023 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $55 → $48 | $38.57 | +24.45% | 3 | Mar 17, 2023 | |
| AMGN Amgen | Upgrades: Overweight | $275 → $265 | $269.98 | -1.84% | 5 | Mar 13, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Overweight | $27 | $11.87 | +127.46% | 1 | Mar 7, 2023 | |
| XENE Xenon Pharmaceuticals | Initiates: Overweight | $50 | $40.50 | +23.46% | 1 | Nov 28, 2022 | |
| FBRX Forte Biosciences | Initiates: Buy | n/a | $0.72 | - | 1 | Mar 26, 2021 | |
| RDUS Radius Health | Maintains: Buy | n/a | $17.90 | - | 1 | Jan 7, 2021 | |
| STTK Shattuck Labs | Initiates: Buy | n/a | $10.59 | - | 1 | Nov 3, 2020 | |
| ADAP Adaptimmune Therapeutics | Maintains: Buy | n/a | $1.08 | - | 1 | Apr 27, 2020 | |
| CALA Calithera Biosciences | Maintains: Buy | n/a | $0.02 | - | 1 | Mar 27, 2020 | |
| AVTR Avantor | Maintains: Buy | n/a | $23.94 | - | 1 | Mar 20, 2020 | |
| BOLD Boundless Bio | Maintains: Neutral | n/a | $11.64 | - | 2 | Dec 10, 2018 |
BioMarin Pharmaceutical
Apr 25, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $80.91
Upside: +35.95%
Neurocrine Biosciences
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $135.99
Upside: +25.01%
Bristol-Myers Squibb Company
Apr 18, 2024
Maintains: Equal-Weight
Price Target: $51 → $52
Current: $44.85
Upside: +15.94%
Merck & Co.
Mar 27, 2024
Maintains: Equal-Weight
Price Target: $130 → $135
Current: $131.20
Upside: +2.90%
Gilead Sciences
Mar 4, 2024
Maintains: Equal-Weight
Price Target: $84 → $78
Current: $65.42
Upside: +19.23%
Ironwood Pharmaceuticals
Mar 1, 2024
Maintains: Overweight
Price Target: $20 → $14
Current: $7.82
Upside: +79.03%
Travere Therapeutics
Feb 16, 2024
Maintains: Equal-Weight
Price Target: $8 → $9
Current: $5.26
Upside: +71.10%
Biogen
Feb 14, 2024
Downgrades: Equal-Weight
Price Target: $315 → $240
Current: $208.90
Upside: +14.89%
Eli Lilly
Feb 7, 2024
Maintains: Overweight
Price Target: $700 → $825
Current: $733.51
Upside: +12.47%
Vertex Pharmaceuticals
Feb 6, 2024
Maintains: Overweight
Price Target: $500 → $540
Current: $397.48
Upside: +35.86%
Pfizer
Oct 17, 2023
Maintains: Equal-Weight
Price Target: $39 → $35
Current: $25.40
Upside: +37.80%
Regeneron Pharmaceuticals
Aug 21, 2023
Maintains: Overweight
Price Target: $875 → $980
Current: $883.20
Upside: +10.96%
Cerevel Therapeutics Holdings
May 4, 2023
Upgrades: Overweight
Price Target: $30
Current: $42.47
Upside: -29.36%
AbbVie
Apr 28, 2023
Maintains: Overweight
Price Target: $200 → $195
Current: $159.62
Upside: +22.17%
Halozyme Therapeutics
Mar 17, 2023
Maintains: Overweight
Price Target: $55 → $48
Current: $38.57
Upside: +24.45%
Amgen
Mar 13, 2023
Upgrades: Overweight
Price Target: $275 → $265
Current: $269.98
Upside: -1.84%
Mineralys Therapeutics
Mar 7, 2023
Initiates: Overweight
Price Target: $27
Current: $11.87
Upside: +127.46%
Xenon Pharmaceuticals
Nov 28, 2022
Initiates: Overweight
Price Target: $50
Current: $40.50
Upside: +23.46%
Forte Biosciences
Mar 26, 2021
Initiates: Buy
Price Target: n/a
Current: $0.72
Upside: -
Radius Health
Jan 7, 2021
Maintains: Buy
Price Target: n/a
Current: $17.90
Upside: -
Shattuck Labs
Nov 3, 2020
Initiates: Buy
Price Target: n/a
Current: $10.59
Upside: -
Adaptimmune Therapeutics
Apr 27, 2020
Maintains: Buy
Price Target: n/a
Current: $1.08
Upside: -
Calithera Biosciences
Mar 27, 2020
Maintains: Buy
Price Target: n/a
Current: $0.02
Upside: -
Avantor
Mar 20, 2020
Maintains: Buy
Price Target: n/a
Current: $23.94
Upside: -
Boundless Bio
Dec 10, 2018
Maintains: Neutral
Price Target: n/a
Current: $11.64
Upside: -